Elan: The Virtues of the Middle
Executive SummaryBig Pharma's growth problems are horrendous; biotech's a crapshoot. Much to everyone's surprise, mid-sized drug companies may have the most options. Having done four modest acquisitions since 1986, Elan has transformed itself and, in the process, shown how middle tier companies can take advantage of licensing and acquisition opportunities big companies can't touch.
You may also be interested in...
The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.
Correvio's atrial fibrillation drug Brinavess will return to a US FDA advisory committee more than a decade after the agency first declined to approve the drug; FDA still has a series of cardiovascular safety concerns related to the drug and is not convinced by data from the European experience.